Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on November 8, 2012. The report serves to announce the Company's financial results for the third quarter of 2012. The filing references a press release (Exhibit 99.1) containing the detailed results.
Key Financial Metrics
The provided text does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of the Q3 2012 results announcement.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. The report explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the specific Q3 2012 financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 Press Release.
- Confirm the Company's current cash runway and burn rate, as these are critical for a clinical-stage biopharmaceutical firm.
- Review the press release for any updates on clinical trial progress or regulatory milestones not detailed in this 8-K summary.
- Note that the financial data in this filing is "furnished" and not "filed," meaning it may not be subject to the same liability standards as audited financial statements.